← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES › PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors
sasanlimab
L01FF16
Adult Dosing
- Loading dose: 1000mg on day 1
- Maintenance dose: 500mg every 2 weeks
- Administer as IV infusion over 30 minutes
Pediatric Dosing
- Safety and efficacy not established
Indications
- Treatment of unresectable or metastatic melanoma
- Treatment of metastatic non-small cell lung cancer
- Treatment of renal cell carcinoma
Mechanism of Action
- Bispecific monoclonal antibody targeting PD-1 and LAG-3
- Enhances antitumor activity by simultaneously blocking PD-1 and LAG-3
Contraindications
- Hypersensitivity to sasanlimab or its components
Adverse Reactions
- Fatigue
- Nausea
- Diarrhea
- Rash
- Pruritus
- Immune-mediated adverse reactions
Drug Interactions
- Concomitant use with immunosuppressive agents may decrease efficacy
- Concomitant use with vaccines may decrease vaccine efficacy
Curated Content: Needs Vetting Before Put to Clinical Use